[{"id":"a744dd9f-e4be-4b72-a2de-da79e8056978","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800964","created_at":"2023-04-06T14:03:12.774Z","updated_at":"2025-02-25T13:55:05.180Z","phase":"Phase 1","brief_title":"Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05800964","lead_sponsor":"Amgen","biomarkers":" MSLN • CDH3","pipe":"","alterations":" ","tags":["MSLN • CDH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AMG 305"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":" Primary completion: 06/10/2027","primary_completion_date":" 06/10/2027","study_txt":" Completion: 02/12/2028","study_completion_date":" 02/12/2028","last_update_posted":"2025-02-20"},{"id":"237b354a-5aa6-4026-9efe-63dba3502553","acronym":"","url":"https://clinicaltrials.gov/study/NCT05451849","created_at":"2022-07-11T11:54:54.962Z","updated_at":"2024-07-02T16:35:16.022Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer","source_id_and_acronym":"NCT05451849","lead_sponsor":"TCR2 Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TC-510"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 06/21/2022","start_date":" 06/21/2022","primary_txt":" Primary completion: 10/30/2028","primary_completion_date":" 10/30/2028","study_txt":" Completion: 10/30/2028","study_completion_date":" 10/30/2028","last_update_posted":"2024-03-06"},{"id":"f8516452-54df-4277-8f56-8aa72d1fb00e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03907852","created_at":"2021-01-18T19:14:14.258Z","updated_at":"2025-02-25T14:28:16.858Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","source_id_and_acronym":"NCT03907852","lead_sponsor":"TCR2 Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 11/02/2028","primary_completion_date":" 11/02/2028","study_txt":" Completion: 11/02/2028","study_completion_date":" 11/02/2028","last_update_posted":"2024-03-06"},{"id":"77e12794-7dd2-4ce2-bacc-b40dca21f7bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05375825","created_at":"2022-05-17T12:54:06.483Z","updated_at":"2024-07-02T16:35:21.326Z","phase":"Phase 1","brief_title":"Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin","source_id_and_acronym":"NCT05375825","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LMB-100"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 02/06/2024","start_date":" 02/06/2024","primary_txt":" Primary completion: 12/18/2024","primary_completion_date":" 12/18/2024","study_txt":" Completion: 12/18/2024","study_completion_date":" 12/18/2024","last_update_posted":"2024-02-01"},{"id":"6c76a251-4026-4ad4-94d6-b2b81e644662","acronym":"","url":"https://clinicaltrials.gov/study/NCT04809766","created_at":"2021-03-22T11:52:20.228Z","updated_at":"2024-07-02T16:35:24.105Z","phase":"Phase 1","brief_title":"Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT04809766","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-A • MSLN","pipe":" | ","alterations":" MSLN expression • HLA-A*02","tags":["HLA-A • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • FH-TCR-Tᴍsʟɴ • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-01-09"},{"id":"5deea24a-3e42-4778-ab8c-7a751c529263","acronym":"","url":"https://clinicaltrials.gov/study/NCT04727554","created_at":"2021-01-29T07:21:48.844Z","updated_at":"2024-07-02T16:35:36.003Z","phase":"Phase 1","brief_title":"Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT04727554","lead_sponsor":"Amgen","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e inezetamab (AMG994) • zeluvalimab (AMG 404)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 04/29/2021","start_date":" 04/29/2021","primary_txt":" Primary completion: 06/05/2023","primary_completion_date":" 06/05/2023","study_txt":" Completion: 06/05/2023","study_completion_date":" 06/05/2023","last_update_posted":"2023-09-22"},{"id":"f384c94c-4626-4812-85bd-523c626b0875","acronym":"","url":"https://clinicaltrials.gov/study/NCT04034238","created_at":"2021-01-18T19:47:53.888Z","updated_at":"2024-07-02T16:35:41.280Z","phase":"Phase 1","brief_title":"Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors","source_id_and_acronym":"NCT04034238","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tofacitinib • LMB-100"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/29/2019","start_date":" 08/29/2019","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 11/19/2021","study_completion_date":" 11/19/2021","last_update_posted":"2023-08-01"},{"id":"9fff9757-a7af-45a1-92b1-4c86a11926c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05403554","created_at":"2022-06-03T12:55:16.390Z","updated_at":"2024-07-02T16:35:47.006Z","phase":"Phase 1","brief_title":"A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers","source_id_and_acronym":"NCT05403554","lead_sponsor":"Light Chain Bioscience - Novimmune SA","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NI-1801"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/29/2022","start_date":" 04/29/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2023-05-29"},{"id":"8c0aa7e0-1334-4262-9265-0f911e6ba67b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05856643","created_at":"2023-05-12T17:04:51.685Z","updated_at":"2024-07-02T16:35:48.170Z","phase":"Phase 1","brief_title":"Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Ovarian Epithelial Carcinoma","source_id_and_acronym":"NCT05856643","lead_sponsor":"Shantou University Medical College","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SZ011"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-05-12"},{"id":"dea692c6-2a2d-42ac-a72b-d9197b7cfc2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05686720","created_at":"2023-01-17T14:59:19.477Z","updated_at":"2024-07-02T16:35:57.570Z","phase":"Phase 1","brief_title":"Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer","source_id_and_acronym":"NCT05686720","lead_sponsor":"First Affiliated Hospital of Shantou University Medical College","biomarkers":" HER-2 • ER • PGR • MSLN","pipe":" | ","alterations":" HER-2 negative • ER negative • MSLN positive • PGR negative","tags":["HER-2 • ER • PGR • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • MSLN positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SZ011"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-01-16"},{"id":"5d5babd2-7c3c-4130-a0da-f4352113269f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02243371","created_at":"2021-01-18T10:31:41.476Z","updated_at":"2025-02-25T14:34:56.150Z","phase":"Phase 2","brief_title":"GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab","source_id_and_acronym":"NCT02243371","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cyclophosphamide • CRS-207 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 01/02/2015","start_date":" 01/02/2015","primary_txt":" Primary completion: 07/21/2017","primary_completion_date":" 07/21/2017","study_txt":" Completion: 07/21/2017","study_completion_date":" 07/21/2017","last_update_posted":"2021-04-06"},{"id":"ed9b78d3-4dd2-490d-a6a7-40b8f9a2f10e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01675765","created_at":"2021-01-18T07:15:14.071Z","updated_at":"2025-02-25T15:52:57.503Z","phase":"Phase 1b","brief_title":"Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma","source_id_and_acronym":"NCT01675765","lead_sponsor":"Aduro Biotech, Inc.","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cyclophosphamide • pemetrexed • CRS-207 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 09/03/2014","start_date":" 09/03/2014","primary_txt":" Primary completion: 09/05/2018","primary_completion_date":" 09/05/2018","study_txt":" Completion: 08/19/2019","study_completion_date":" 08/19/2019","last_update_posted":"2020-09-30"},{"id":"78316ab0-ca27-4841-8b3c-30534afe4786","acronym":"","url":"https://clinicaltrials.gov/study/NCT01362790","created_at":"2021-01-18T05:34:37.494Z","updated_at":"2024-07-02T16:36:59.049Z","phase":"Phase 1/2","brief_title":"SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma","source_id_and_acronym":"NCT01362790","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • MSLN","pipe":" | ","alterations":" EGFR mutation • MSLN expression • ALK translocation","tags":["ALK • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSLN expression • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • pentostatin • SS1(dsFv)-PE38 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 05/11/2011","start_date":" 05/11/2011","primary_txt":" Primary completion: 08/03/2016","primary_completion_date":" 08/03/2016","study_txt":" Completion: 08/07/2017","study_completion_date":" 08/07/2017","last_update_posted":"2019-06-06"},{"id":"38a358aa-4637-4d62-88fe-5f1f4ce41f8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03692637","created_at":"2021-01-18T18:05:54.027Z","updated_at":"2024-07-02T16:37:03.340Z","phase":"Phase 1","brief_title":"Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer","source_id_and_acronym":"NCT03692637","lead_sponsor":"Allife Medical Science and Technology Co., Ltd.","biomarkers":" PD-L1 • PD-1 • MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["PD-L1 • PD-1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN CAR-T • anti-Mesothelin CAR NK Cells"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 11/01/2020","primary_completion_date":" 11/01/2020","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2019-01-31"},{"id":"5ffa588d-80e3-48b3-a0ca-8762fe967b5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01355965","created_at":"2021-01-18T05:32:44.059Z","updated_at":"2024-07-02T16:37:17.719Z","phase":"Phase 1","brief_title":"Autologous Redirected RNA Meso-CIR T Cells","source_id_and_acronym":"NCT01355965","lead_sponsor":"University of Pennsylvania","biomarkers":" TNFA","pipe":"","alterations":" ","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e autologous redirected RNA meso-CIR T cells"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 05/01/2011","start_date":" 05/01/2011","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2017-09-19"},{"id":"6d824741-8753-4959-8949-c14b740d29dc","acronym":"MORAb-009-006","url":"https://clinicaltrials.gov/study/NCT01521325","created_at":"2021-01-18T06:24:00.019Z","updated_at":"2024-07-02T16:37:28.752Z","phase":"Phase 1","brief_title":"A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers","source_id_and_acronym":"NCT01521325 - MORAb-009-006","lead_sponsor":"Morphotek","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e amatuximab (MORAb-009)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 03/01/2013","primary_completion_date":" 03/01/2013","study_txt":" Completion: 03/01/2013","study_completion_date":" 03/01/2013","last_update_posted":"2016-09-30"}]